TABLE 2.
Base-case analysis results.
| Strategy | Cost | Incr cost | LYs | Incr LYs | ICER/LYs | QALYs | Incr QALYs | ICER/QALYs |
|---|---|---|---|---|---|---|---|---|
| All patient group | ||||||||
| Chemotherapy | 4190.37 | — | 0.73 | — | — | 0.53 | — | — |
| Sintilimab + chemotherapy | 17671.77 | 13481.39 | 1.79 | 1.06 | 12718.29 | 1.17 | 0.64 | 21024.05 |
| PD-1 CPS≥10 group | ||||||||
| Chemotherapy | 4300.36 | — | 0.75 | — | — | 0.55 | — | — |
| Sintilimab + chemotherapy | 18272.87 | 13972.51 | 1.85 | 1.10 | 12702.28 | 1.21 | 0.67 | 20974.23 |
Abbreviation: Incr cost, incremental cost; Lys, life-years; Incr Lys, incremental life-years; QALYs, quality-adjusted life-years; Incr QALYs, incremental quality-adjusted life-years; ICER, incremental cost-effectiveness ratio; PD-L1, programmed cell death-ligand 1